Ticker LaunchIPO · HARP
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. (HARP) priced its initial public offering on Feb 8, 2019 at $14.00 per share, within its $13.00–$15.00 range, raising $75.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $334.7M. Cooley advised the company and Latham & Watkins advised the underwriters.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company developing T cell engagers, built on its TriTAC platform, that direct a patient's T cells to kill cells carrying specific antigens. Its lead candidate, HPN424, is in a Phase 1 trial for metastatic castration-resistant prostate cancer.
- Status
- IPO
- Ticker
- HARP
- Exchange
- Nasdaq Global Select
- Priced
- Feb 8, 2019
- IPO price
- $14.00
- Price range
- $13.00–$15.00
- Raised
- $75.6M
- Market cap at IPO price
- $334.7M
- First filed
- Dec 27, 2018
- Company counsel
- Cooley
- Underwriters' counsel
- Latham & Watkins
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Dec 27, 2018
- Latest amendment Feb 4, 2019
- Final prospectus (424B4) Feb 8, 2019
- All filings on EDGAR CIK 1708493
Other Biotech & pharma IPOs in 2019
- Stealth BioTherapeutics CorpMITO · Feb 15, 2019 · $78M
- Rocket One Inc.HOTH · Feb 15, 2019 · $7M
- TCR2 Therapeutics Inc.TCRR · Feb 15, 2019 · $75M
- Avedro IncAVDR · Feb 14, 2019 · $70M
- Gossamer Bio, Inc.GOSS · Feb 8, 2019 · $276M
- Alector, Inc.ALEC · Feb 7, 2019 · $175.8M